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Abstract
CD4 + count increase has been reported to be different with lopinavir/r (LPV/r) and efavirenz (EFV)-containing
regimens. The different effect of these two regimens on other immune function parameters and the relationship
with the gain of CD4+ count have not been assessed in a randomized clinical trial. Fifty antiretroviral treatment
(cART) naı¨ve HIV-infected individuals were randomized to receive LPV/r or EFV both with tenofovir/em-
tricitabine for 48 weeks. A substudy of immunological function restoration was performed in 22 patients (LPV/r
n = 10 and EFV n= 12). Activation, thymic function, apoptosis, senescence, exhaustion, Treg cells, interleukin
(IL)-7-receptor/IL-7 system, thymic volume, and lymphoid tissue fibrosis were evaluated at baseline and at
week 48. Both groups experienced a CD4+ count increase that was higher in the EFV group (DCD4 + 88 vs. 315
cells/ll LPV/r vs. EFV, respectively, p< 0.001). Despite this difference in CD4+ gain, the change in other
immune function parameters was similar in both treatment groups. Most of parameters evaluated tended to
normalize after 48 weeks of cART. A significant decrease in levels of activation, senescence, exhaustion, and
apoptosis on CD4+ and CD8+ T cells ( p< 0.001 for all) and a significant increase in markers of thymic
function, IL-7 receptor, and in the levels of central memory CD4+ T cells and naive subsets of CD8+ T cells
( p< 0.001 for all) with respect to baseline values were observed without any difference between groups. These
data indicate that the differences in CD4+ gain with different cART regimens are not immunologically
meaningful and might explain the similar clinical efficacy of these regimens.
Introduction
Combined antirretroviral treatment (cART) leads tocontinued viral suppression and immune recovery that
reduces HIV-associated morbidity and mortality.1 Two nu-
cleoside retrotranscriptase inhibitors (NRTI) combined with
either a boosted protease inhibitor (PI) or with a non-
nucleoside retrotranscriptase inhibitor (NNRTI) are the
standard of care for initiating therapy.2 Several studies have
compared virological efficacy and immune reconstitution of
different cART regimens. The ACTG 5142 study described a
higher increase of CD4 + T lymphocytes counts from baseline
in the PI regimen (lopinavir-ritonavir: LPV/r) compared with
the efavirenz (EFV) regimen after 96 weeks of treatment (but
not after 48 weeks of cART).3 Similar findings have been
reported in other cohort studies.4–6 Conversely, other clinical
trials that compared NNRTI and PI-based regimens did not
find significant differences in the increases in CD4 + counts in
both groups.7–9
It is unclear if the potential differences in recovery of the
CD4 T cell count with different cART regimens have any
clinical or immunological relevance. First, regarding different
clinical outcomes with EFV vs. LPV/r-containing regimens, it
has been reported that PI- and NNRTI-based cART regimens
are equally effective in protection against Kaposi sarcoma.10
However, some cohort studies showed that PI regimens
boosted with ritonavir (RTV) were associated with a 2-fold
higher rate of AIDS/death (HR, 2.07) than EFV-containing
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regimens, although it is possible that confounding factors
could be responsible for an overestimate of the true risk as-
sociated with boosted PI regimens.11 Second, there are data
suggesting that clinically important CD4+ T cell count re-
sponses are likely to be better defined in terms of absolute post-
cART CD4+ T cell counts rather than change from baseline.12
Finally, the effect of different regimens on parameters in-
volved in immune function and their relationship with differ-
ent gains of CD4+ have not been assessed in a randomized
clinical trial. Moreover, most previous studies addressing the
effect of cART on immune restoration have analyzed only a
few of the multiple parameters altered in HIV infection.13–18
Therefore, we performed a comprehensive approach of si-
multaneous measurement of different immunological param-
eters in CD4+ and CD8+ T cells in a subset of 22 patients out
of 50 cART-naive HIV-infected individuals who were ran-
domized to receive LPV/r or EFV both with tenofovir/
emtricitabine for 48 weeks. The final objective of the study
was to analyze if with a similar level of HIV suppression,
different treatment regimens induce different degrees of im-
munological function restoration.
Materials and Methods
Study population
This is a substudy conducted in a subset of 22 patients out
of 50 cART-naive HIV-infected individuals who were ran-
domized to receive LPV/r or EFV both with tenofovir/em-
tricitabine for 48 weeks at two different Hospitals (Hospital
Clinic and Hospital Germans Trias i Pujol) in Barcelona,
Spain. Twenty-eight additional patients were recruited in
three other hospitals and did not participate in this substudy.
There were no differences at baseline between patients in-
cluded and excluded from the study. Twelve patients re-
ceived efavirenz (EFV group) and 10 lopinavir/ritonavir
(LPV/r group) with a backbone of tenofovir plus em-
tricitabine. To participate in the study, written informed
consent was obtained from all individuals, and the study
protocol was evaluated and approved by the Hospitals Ethical
Committee.
Viral load measurement
Plasma HIV-RNA was measured using Versant HIV-1
RNA v3.0 (Siemens, Barcelona, Spain), which has a lower
limit of detection of 50 copies/ml.
Cell samples
All analyses were done in cryopreserved peripheral blood
mononuclear cells (PBMCs). EDTA-anticoagulated blood
was obtained by venipuncture; PBMCs were immediately
isolated by density gradient centrifugation using Ficoll-
Hypaque (Sigma Chemical Co., St. Louis, MO) and frozen in
FCS plus 10% DMSO. The viability of thawed PBMCs was
always greater than 85%. Analyses were performed in two
cell samples from each patient: at baseline and 48 weeks after
cART initiation
Immunophenotypic analysis
We used a comprehensive approach of simultaneous mea-
surement of different immunological parameters in CD4+ and
CD8+ T cells: differentiation stage (using CD45RA and
CD27 markers), activation level (using CD38 and HLADR
markers), thymic function (using CD31 marker), apoptosis
level (using annexin binding), exhaustion level (using PD-1
and Tim-3 markers), level of senescence (using CD57 mark-
er), interleukin (IL)-7 receptor/IL-7 system (using CD127
marker and measuring the plasma level of IL-7), and T reg-
ulatory (Treg) cells level (using CD25, CD127, and FoxP3
markers). All parameters were evaluated using five-color flow
cytometry.
PBMCs from each patient were stained with proper anti-
bodies according to eight different antibody panels. Amillion
PBMCs were washed with 2ml of phosphate-buffered saline
(PBS) and stained for surface markers by incubation with the
appropriate antibody panel for 30min at 4C. For antibody
panels one to seven cells were then washed with 2ml of PBS
and resuspended in 250ll of PBS. For antibody panel 8
(apoptosis) cells were first stained for surface markers as
described above, then washed in PBS, resuspended in 250ll
annexin binding buffer, and then incubated with annexin (BD
Biosciences, San Diego, CA). For antibody panel 9 (Treg
cells), cells were first stained with surface markers as de-
scribed above, washed with PBS, and resuspended in cytofix/
cytoperm solution (BD Biosciences, San Diego, CA) for
20min at 4C. The permeabilized cells were washed with
2ml of Perm/Wash Buffer (BD Biosciences) and stained for
intracellular FoxP3-FITC (eBioscience, San Diego, CA)
marker at 4C for 30min.
After intracellular marker staining, cells were washed with
2ml of Perm/Wash buffer and resuspended in 250ll PBS.
Five-color acquisition was performed on Cytomics FC 500
flow cytometer (Beckman Coulter, Fullerton, CA). For each
sample, a minimum of 50,000 CD4 + and 50,000 CD8 +
events were acquired. Data analysis was performed using
CXP software (Beckman Coulter, Fullerton, CA). Gating was
done on CD8 + bright and CD4 + cells. Based on the expression
of CD45RA and CD27 markers, four different differentiation
stage subsets of CD4 + and CD8 + cells were defined (see
Table 2): naive (CD45RA +CD27 + ), central memory
(CD45RA -CD27 + ), effector memory (CD45RA -CD27 - ),
and effector (CD45RA +CD27- ) cells. Activation, apoptosis,
CD31, CD127, and CD57 expression were assessed in total
CD4 + and CD8 + and in each of these four differentiation
FIG. 1. Representative example of flow cytometry data and gating strategy. A representative example for some of the
antibody panels used is shown. (A) Expression of CD45RA and CD27 on CD4 and CD8 T cells to define the differentiation
stage of these cells. (B, C) Expression of activation markers CD38 and HLA-DR on different subsets of CD4 (B) and CD8
(C) T cells as defined by CD45RA and CD27 expression. (D, E) Annexin binding on different subsets of CD4 (D) and CD8
(E) T cells as defined by CD45RA and CD27 expression. (F) Expression of exhaustion markers PD-1 and Tim-3 on CD4
and CD8 T cells. (G) Gating strategy used to define T regulatory (Treg) CD4 cells as CD127 -CD25 +FoxP3 + . Numbers
inside plots or histograms represent the percentage of positive events in each quadrant or region.
‰
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stage subsets. Exhaustion level was assessed in total CD3 +
and in total CD3 +CD4 + and CD3 +CD8 + cells. Treg cells
were defined as CD4 +CD127 -CD25 +FoxP3 + cells. Dot
plots explaining the flow cytometry gating strategy for de-
fining different T cells subsets can be seen in Fig. 1.
Plasma interleukin (IL)-7 levels
IL-7 was measured using a highly sensitive commercial
immunoassay (Quantikine HS, R&D Systems, Barcelona,
Spain), which has a lower limit of detection of 0.1 pg/ml
following the manufacturer’s instructions.
Lymphoid tissue
Tonsillar biopsy was performed in eight patients at base-
line and 48 weeks after cART initiation. Tonsillar tissue was
formalin-fixed and paraffin-embedded for histological study.
A trichrome stain, using the Masson method, was used to
identify collagen fibers.
Lymphoid tissue collagen deposition was assessed using
the Olympus Cell-B Basic Imaging Software (Olympus
Corporation, Shinzuku, Tokyo, Japan). From each specimen,
the follicular area, defined as the proportion of follicular areas
with respect to the total amount of lymphoid tissue, was
evaluated by morphometry from low-power fields ( · 10 ob-
jective). To quantify collagen fibers, 10 images from 10 high-
power fields (HPFs) (· 40 objective) from interfollicular
areas were captured on trichrome-stained slides and the
percentage of lymphoid tissue occupied by collagen was
determined.
Volume and thymic index
Noncontrast chest computerized tomography (CT) was
performed in 11 patients at baseline and 48 weeks after cART
initiation on a CT scanner (Somatom Sensation 64, Siemens,
Erlangen, Germany) with contiguous 5-mm sections. Mea-
surements were always performed by the same radiologist as
previously described.19 Thymic tissue in all the slices was
carefully delimited on a Leonardo Workstation (Siemens,
Erlangen, Germany) obtaining the thymic area in each slice.
The thymic areas were multiplied by the slice thickness to
obtain the thymic volume in cubic centimeters. Additionally,
thymic tissue was scored on a grading scale of 0–5: 0—no
soft tissue, with the thymus entirely replaced by fat; 1—
minimal soft tissue, barely recognizable; 2—minimal soft
tissue, more obvious; 3—moderate soft tissue; 4—moderate
soft tissue of greater extent, almost mass like; and 5—mass-
like appearance, of concern for hyperplasia or thymoma.20
Statistical analyses
Characteristics of the study population and the different
immunological parameters were recorded as median (in-
terquartile range), and comparisons were made using the
nonparametric tests Mann–Whitney U-test or Wilcoxon test
as appropriate. Correlations between quantitative parame-
ters were explored using the Spearman’s rho test. All sta-
tistical analyses were performed using SPSS software
version 13 (SPSS Inc., Chicago, IL). All p values were two-
tailed, and were considered significant when lower than
0.05.
Results
Study population
Twenty-two patients were included in the immunological
study. There were no differences in terms of age, sex, base-
line CD4 + counts, and HIV-RNA viral load or frequency of
hepatitis C virus (HCV) coinfection compared to the popu-
lation of the main study (data not shown). Of the 22 patients
included, 12 received an EFV-containing regimen and 10 an
LPV/r-based cART. There were no significant differences
between both treatment groups in terms of age, sex, baseline
CD4 + counts, baseline HIV-RNA load, and frequency of
HCV coinfection (Table 1). All patients reached undetectable
HIV plasma viremia and remained so during 48 weeks of
therapy. There were no differences in absolute CD4 + count at
week 48 (median 530 vs. 641 cells/ll, LPV/r vs. EFV groups,
respectively, p = 0.25) (Table 1).
Comparison of immunological parameters at baseline
between EFV and LPV/r groups of patients
Different T cell subsets were analyzed grouped in nine
different functional categories: T cell differentiation, acti-
vation of CD4 + and CD8 + T cells, thymic function (using
CD31 as a marker of recent thymic emigrants), expression of
IL-7 receptor (CD127), T cell senescence (using CD57
marker), T cell exhaustion (using PD-1 and Tim-3 markers),
T cell apoptosis (using annexin binding), and Treg cells
(CD4 +CD25 +FoxP3 +CD127 - ) (Table 2).
Levels of these parameters at baseline were compared
between LPV/r and EFV groups of patients. Both groups
were comparable for most of the parameters analyzed, with
significant differences only for a few of them. Of these pa-
rameters, some were significantly increased in the EFV group
(level of CD8 + central memory cells, CD31 expression on
different subsets of CD8 + cells, and PD-1 expression on
Table 1. Baseline Characteristics of Patients Included in the Study
Variable NNRTI-based cART (n = 12) PI-based cART (n = 10) p-value
Age (years)a 35 (31–45) 40 (35–44) 0.4
Sex (M/F) 12/0 10/0 NA
Baseline CD4 counta (median cell/ll) 317 (228–422) 407 (269–526) 0.23
Baseline HIV-RNAa (median log copies/ml) 4.5 (4.3–5.0) 4.9 (4.2–5.2) 0.47
CD4 count at week 48a (median cells/ll) 641 (474–736) 530 (446–619) 0.25
HCV coinfection (%) 8% (1/12) 0% (0/10) 1
aMedian (interquartil range).
NNRTI, nonnucleoside reverse transcriptase inhibitor; CART, combined antiretroviral treatment; PI, protease inhibitor; HCV, hepatitis C virus.
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CD4 + cells) and some others were significantly increased in
the LPV/r group (level of CD8 + effector cells, CD127 ex-
pression on effector CD4 + cells, and CD57 expression on
CD8 + cells) (data not shown).
Evolution of immunological parameters after cART
in the whole population of patients
The evolution of all parameters analyzed was measured as
the difference between baseline and week 48 of therapy
values (delta values). In the whole population of patients
most of the parameters significantly changed after cART. In
parallel with the significant increase in CD4 + counts after 48
weeks of therapy [from median (IQR) 360 (252–429) to 592
(452–714) cells/ll, p < 0.0001] there was a significant in-
crease in the central memory subset of CD4 + T cells and a
significant decrease in the effector memory subset of CD4 + T
cells, as well as a significant increase in naive and in effector
subsets of CD8 + T cells and a significant decrease in the
effector memory subset of CD8 + T cells (Fig. 2A).
Activation levels significantly decreased after cART in the
majority of the different CD4 + and CD8 + T cell subsets, and
the decrease was especially noticeable for the subsets coex-
pressing both CD38 and HLA-DR activation markers (Fig.
2B). Interestingly, the extent of decrease of these CD38 +
HLA-DR + subsets was much higher in CD8 + than in CD4 +
T cell subsets (Fig. 2B), most likely because baseline levels
for these subsets were higher in CD8 + than in CD4 + T cells
(data not shown). Surprisingly, the levels of effector memory
and effector subsets of CD4 + and CD8 + T cells expressing
only HLA-DR + (CD38 -HLA-DR + ) significantly increased
after cART (Fig. 2B).
Other immunological functions (Supplementary Table S1;
Supplementary Data are available online at www.liebertpub
.com/aid) that showed a significant decrease were T cell se-
nescence, T cell exhaustion, and T cell apoptosis. A decrease
of senescence after cART was observed in naive and central
memory subsets of both CD4 + and CD8 + T cells, with much
higher variation in CD8 + subsets, probably due to much
higher levels of senescence at baseline in CD8 + subsets than
in CD4 + subsets (Fig. 2C). The decrease in T cell exhaustion
was observed in both CD4 + and CD8 + T cells (Fig. 2C), as
well as in total CD3 + T lymphocytes, and it was restricted to
the PD-1 marker with no variation in Tim-3 expression.
Overall, Tim-3 expression was only marginal both at baseline
and after cART (data not shown). Lastly, the levels of apo-
ptosis also experienced a significant decrease after cART in
CD4 + and CD8 + T cells (Fig. 2C) as well as in most subsets
of these cells (data not shown).
In contrast to what was observed for activation, senes-
cence, exhaustion, and apoptosis, other immunological
functions significantly increased after cART. This was best
exemplified by CD127 expression with a significant in-
crease in central memory CD4 + T cells and in all but ef-
fector subsets of CD8 + T cells. The highest increase was
observed in central memory CD8 + T cells (Fig. 2D). Re-
garding thymic function, there was a significant increase
of CD31 expression on naive CD4 + and CD8 + T cells (Fig.
2D). There was also a small but significant decrease in the
level of T regulatory cells in the whole study population.
(Fig. 2D).
Comparison of evolution after cART of immunological
parameters between EFV and LPV/r groups of patients
With the hypothesis that with a similar level of HIV sup-
pression, different treatment regimens could induce different
degrees of immunological function restoration, we compared
the evolution of different immunological parameters between
patients treated with LPV/r and EFV-based cART regimens.
For this purpose, we compared the variation (delta value, D,
defined as the difference between baseline value and after 48
Table 2. T Cell Subsets Analyzed in the Study, Grouped According to Eight Different Categories
T cell subset category (antibody panel) T cell subset
Differentiation stage of CD4 and CD8 cells (CD3-FITC/
CD27-PE/CD45RA-ECD/CD8-PECy5/CD4-PECy7)
CD4 and CD8 cells (total)
Naive cells (CD45RA +CD27 + )
Central memory cells (CD45RA -CD27 + )
Effector memory cells (CD45RA -CD27 - )
Effector cells (CD45RA +CD27 - )
Activation of CD4 and CD8 T cells (including naive,
central memory, effector memory, and effector cells)
(HLADR-FITC/CD27-PE/CD45RA-ECD/CD38-
PECy5/CD4-PECy7 or CD8- PECy7)
CD38 +DR -
CD38 +DR +
CD38 -DR +
Thymic function (CD31) (CD31-FITC/CD27-PE/
CD45RA-ECD/CD8-PECy5/CD4-PECy7)
CD31 expression on CD4 and CD8 cells (including
naive, central memory, effector memory, and effector cells)
Expression of CD127 (CD127-FITC/CD27-PE/
CD45RA-ECD/CD8-PECy5/CD4-PECy7)
CD127 expression on CD4 and CD8 cells (including
naive, central memory, effector memory, and effector cells)
Senescence (CD57) (CD57-FITC/CD27-PE/
CD45RA-ECD/CD8-PECy5/CD4-PECy7)
CD57 expression on CD4 and CD8 cells (including
naive, central memory, effector memory, and effector cells)
Exhaustion (PD-1 and Tim-3) of CD3, CD4, and CD8
T cells (CD4-FITC/Tim-3-PE/CD3-ECD/CD8-PECy5/
PD-1-biotin/streptavidin-PECy7)
PD-1 +Tim-3-
PD-1 +Tim-3+
PD-1 -Tim-3+
Apoptosis (annexin binding) (annexin-FITC/CD27-PE/
CD45RA-ECD/CD8-PECy5/CD4-PECy7)
Annexin + binding on CD4 and CD8 cells (including
naive, central memory, effector memory, and effector cells)
T regulatory cells (FoxP3-FITC/CD127-PE/CD8-ECD/
CD25-PECy5/CD4-PECy7)
CD4 +CD25 +CD127 -FoxP3 + cells
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weeks of cART value) of each parameter between both
groups of patients. Both arms experienced a significant CD4
count increase that was significantly higher in the EFV group
[median (IQR) DCD4 88 (34–331) vs. 315 (219–359) cells/ll
LPV/r vs. EFV, respectively, p< 0.001]. Despite the differ-
ence in CD4 count increase, there were no significant dif-
ferences in the delta values between the two groups for the
majority of evaluated parameters, suggesting a very similar
degree of immunological function restoration. Significant
differences between the two groups were observed in only a
FIG. 2. Box-plot graphs showing baseline (light gray boxes) and week 48 (dark gray boxes) levels of different T cell subsets
in the whole population of patients. Vertical axes represent the proportion of cells and horizontal axes the different CD4 and
CD8 T cells subsets. (A) Differentiation stage (coexpression of CD45RA and CD27) of CD4 and CD8 T cells. (B) Activation
(coexpression of CD38 and HLA-DR) of different CD4 and CD8 T cells subsets. (C) Senescence (CD57 expression),
exhaustion (PD1 expression), and apoptosis (Annexin binding) of different CD4 and CD8 T cell subsets. In this graph the right
vertical axis applies only to senescence of CD4 T cells subsets. (D) CD127 expression, thymic function (CD31 expression),
and Treg cells (defined as CD4+CD127-CD25+FoxP3+ ). In this graph the right vertical axis applies only to Treg cells.
Levels of statistical significance for the pairwise comparison (Wilcoxon signed rank test) between baseline and week 48 values
are as follows: p< 0.05 (*); p< 0.01 (**); p< 0.001 (***). N, naive; CM, central memory; EM, effector memory; Ef, effector.
FIG. 3. Box-plots showing the variation (delta value) in the level of different subsets of T cells after 48 weeks of successful
antiretroviral therapy in patients treated with an efavirenz (EFV)-based combined antiretroviral treatment (cART) regimen (light
gray boxes) and in patients treated with a lopinavir/r (LPV/r)-containing cART regimen (dark gray boxes). Positive delta values
reflect an increase and negative values reflect a decrease in the level of the T cell subset. The y-axis scale on the right applies only
to the last subset shown on the x-axis. The dotted line marks the zero delta value. Only T cell subsets with statistically significant
differences ( p£ 0.05) or showing a trend ( p£ 0.1) between EFV and LPV/r groups of patients are shown. CM, central memory
T cells; EM, effector memory T cells; Ef, effector T cells.
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few parameters. Thus, EFV patients experienced lower in-
creases of central memory CD4 + T cells and lower decreases
of apoptosis in effector CD8 + T cells and naive CD4 + T cells
than LPV/r patients (Fig. 3). However, EFV patients expe-
rienced a higher increase of CD127 expression in different
subsets of CD4 + and CD8 + T cells compared to LPV/r pa-
tients ( p= 0.03, p = 0.1, p= 0.05, p = 0.01) (Fig. 3). Regarding
plasma levels of IL-7, interestingly we observed a trend to a
decrease after cART in the EFV group [10.5 (7.2–15.5)
versus 7.4 (4.2–12.6) pg/ml, at baseline and at week 48 re-
spectively, p= 0.06] whereas there was no change in the LPV/
r group [9.8 (6.3–11.9) versus 10.8 (3.7–13.3) pg/ml, at
baseline and at week 48 respectively, p = 0.8].
Lymphoid tissue collagen deposition
Biopsies of eight patients (three on LPV/r and five on EFV)
were suitable for analysis. At baseline patients on LPV/r had
a lower percentage of fibrosis than patients on EFV [0.65
(0.5–2.35) vs. 3.76 (0.21–4.05)]. No significant changes were
observed after 48 weeks on cART [2.21 (0.24–4.05) and 4.90
(2.89–16.96) ( p = 0.123) for week 0 and week 48 respectively
in all patients] (Fig. 4A).
Volume and thymic index
Eleven patients were analyzed with mediastinal CT scans
(five were on LPV/r and six on EFV). The median (IQR)
thymic volume did not change significantly from baseline to
week 48 after cART initiation [week 0: 6.73 cm3 (1.90–13.92)
and week 48: 7.60 cm3 (1.00–18.50) ( p= 0.611)] (Fig. 4B).
Discussion
This is the first time that an evaluation of the recovery of
complete immunohistological function was performed with
simultaneous measurement of different immunological pa-
rameters in CD4 + and CD8 + T cells, thymic volume, and
fibrosis in lymphoid tissue in a randomized clinical trial
comparing LPV/r and EFV. Overall, despite a different gain
of CD4 count, a similar degree of restoration of immuno-
logical function was observed in both treatment groups. We
have employed a comprehensive approach of simultaneous
measurement of different immunological parameters in
CD4 + and CD8 + T cells at baseline and after 48 weeks of
cART in a subset of 22 patients out of 50 cART-naive HIV-
infected individuals who were randomized to receive LPV/r
or EFV both with tenofovir/emtricitabine for 48 weeks.
Overall, we have observed a significant immune restoration
in the whole cohort. As described by other authors, after 48
weeks of cART, we observed an increase of central memory
CD4 + T cells,21–23 thymic recent emigrants,24 and CD127
(IL-7 receptor involved in T cell homeostasis) expression
on T cells,25,26 as well as a decrease of effector memory
T cells,27 Treg cells,28 and markers of activation, senescence,
exhaustion, and apoptosis.13–15,29 However, as reported pre-
viously by our group and other authors, cART did not have an
effect on lymph node fibrosis after 1 year of treatment.30–33
These data indicate that collagen deposition may limit
complete immune reconstitution (although we did not in-
clude a control group of healthy individuals to test to what
extent immune recovery was complete) and that additional
therapeutic strategies are needed to overcome this problem
and improve immune recovery.
Some studies3–6 have described a higher increase of CD4 +
T lymphocyte counts from baseline in the LPV/r regimen as
compared with the EFV regimen. Conversely to what has
been shown in these studies,3–6 we found that the CD4 +
count increase was significantly lower in the LPV/r group
despite the fact that all the patients had an undetectable level
of plasma viremia after 48 weeks of cART. The Lake study
also showed that patients on LPV/r-containing regimens had
a lower CD4 + count increase, although the differences were
not significant.7 It is likely that the discrepancy in the results
of the Lake study and our clinical trial as compared with the
rest of the studies could be due to the small number of patients
included. However, it could not be excluded that the higher
increase in the expression of CD127 in T cell subsets in
the EFV group observed in our clinical trial could also ex-
plain this difference, since expression of CD127 has been
FIG. 4. (A) Box-plots showing the variation in the level of
collagen deposition as measured as percentage of lymphoid
tissue occupied by collagen at baseline before any anti-
retroviral therapy and after 48 weeks of therapy. Patients on
LPV/r and EFV-containing regimens are shown together
(n = 8). (B) Box-plots showing the variation in the level of
thymic volume at baseline before any antiretroviral therapy
and after 48 weeks of therapy. Patients on LPV/r and EFV-
containing regimens are shown together (n= 11).
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previously associated with CD4 gains in treated patients.26
Interestingly, only in the EFV group of patients, in whom a
higher increase in CD127 expression and in CD4 counts was
found, was a decrease of IL-7 plasma levels observed, in
agreement with the homeostatic role of this molecule.
In any case, despite this difference in the delta level of
increase of the CD4 count between the EFV and LPV/r
groups of patients in our study, the degree of restoration of
immunological function was similar in both treatment
groups. Remarkably, we did not observe a significant dif-
ference in the absolute CD4 + count at week 48 between both
groups. Our data would support the hypothesis that clinically
important CD4 + T cell count responses are likely to be better
defined in terms of absolute post-cART CD4 + T cell counts,
rather than change from baseline,12 and would explain why
most of the studies have not shown meaningful clinical out-
come differences between NNRTI and PI regimens.
The main drawback of our study was the small number of
patients included in each group. Other authors have also
found that restoration of immunological function is similar
with different cART strategies.13–18 However, none of them
performed a comprehensive analysis of different T cell sub-
sets grouped in eight different functional categories and
correlated the differences in total gain of CD4 + T cells with
the degree of recovery of other immunological parameters.14–18
Another limitation of our study was that we did not take
samples from mucosal tissues (i.e., rectal biopsies). The
relevance of gut in the immunopathogenesis of HIV infec-
tion and immune recovery with cART is well known. Data
about changes in the intestinal mucosal immune system and
viral load with different cART regimens deserve further in-
vestigation.
In summary, despite the difference in absolute CD4 + in-
crease between LPV/r and EFV-containing regimens, our
data indicate that in patients with a similar level of HIV
immunosuppression the degree of restoration of immuno-
logical function (including immune activation) with cART is
similar in both treatment groups. Although this is a study with
a low number of patients, these data support the fact that the
differences in absolute CD4 + gain with different cART
regimens are not immunologically meaningful and explain
the similar clinical efficacy of the regimens. Larger clinical
trials would be needed to confirm these results.
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